Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:6502:0:b0:439:fcfb:30e with SMTP id x2csp631844wru; Wed, 25 Mar 2026 08:47:00 -0700 (PDT) X-Received: by 2002:a05:622a:858e:b0:509:144a:43bd with SMTP id d75a77b69052e-50b6ed43393mr82410211cf.3.1774453619946; Wed, 25 Mar 2026 08:46:59 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774453619; cv=none; d=google.com; s=arc-20240605; b=g6lrwGIp6RXMAu0fntd7FWQcn7diWaPoi40Vwf1P2mKMn56ZhaNc6MKlodKk4liQN4 nVZg1PMdKZfLZ3ghCvgMKfOW8fW9eUErO04k9EnRaO47sMR4cZBax3LzR3EnVHk2LdWE /R7Bu2nwL8bE9mHCltUuE6p9QlirmuEgCEjLpLUlkACvSY4Gaf4I+oRT/d/AMRrpcJPl Yfv+k9VivosZEsNK/Rf5sIVOAEvN80nSBUixNKxc6juY8kAsCjQfmrM/6SVHsOEhfMV3 JRZI14YNKnfpsEX1YCqecK9sZOE5wC3o2mi+FPhc6a2zVwsgj0Bu7L8rEEagLSvEt4u+ 9d2Q== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=QlVvGqcwTWnjtiPgMXbtOTFaYx6UFRPdEulQrTJG0qU=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=betlYL1en2mZXxs4plkDhkUUKfXJHf1ZxvVQM20v+47F+9ry/WT8Z87cv4C8/r0nri jbtjCYCF/xVvWZDpV+mKdprHUFFQyNSpi2ANwUwQ2t33onfQG95O7lR2RY6Z6MAKK7MF e5tuqOkpQOk2eky5L62FURFQRxM1VZ4snFwYVN/6UrtC+R4BYFTlK2/PmS6v8z0j4ENq MG+g6dxlyGqWsZ8Nyqx1J01JiYBwmFgbLSYsMCVhneimknEY9dX5Vqmm+5TDPINnozXU uBRyzP7I/eFvwC/D55tHighWukJyIV8hqQCup03Mh/xMufLWLpwidkj4h+6io6u+hQyl FWIA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b=VGXJwn3g; dkim=pass header.i=@mailgun.org header.s=mg header.b=GeVHxiZ3; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 159.112.244.47 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v547.v5375b7fa.use4.send.mailgun.net (v547.v5375b7fa.use4.send.mailgun.net. [159.112.244.47]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-89cd582b3f3si892726d6.15.2026.03.25.08.46.59 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Wed, 25 Mar 2026 08:46:59 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 159.112.244.47 as permitted sender) client-ip=159.112.244.47; Authentication-Results: mx.google.com; dkim=pass header.i=@mg2.substack.com header.s=mailo header.b=VGXJwn3g; dkim=pass header.i=@mailgun.org header.s=mg header.b=GeVHxiZ3; spf=pass (google.com: domain of bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com designates 159.112.244.47 as permitted sender) smtp.mailfrom="bounce+a6cce7.4d1858-tjphuhs=gmail.com@mg2.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg2.substack.com; q=dns/txt; s=mailo; t=1774453619; x=1774460819; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=QlVvGqcwTWnjtiPgMXbtOTFaYx6UFRPdEulQrTJG0qU=; b=VGXJwn3gElYYji4MD6FfNjzQRRujt7hFCjUUeZa2A2bKNsSQNpteEDuboHIBx8ryP9+RcqH+CaNA2G0QSfUdClX/ZfCkeCCHeCAKBD6qFL/Aleaai/XEMkIXaDX5nfVlmthPeE4RyplpSLnlAyP2XWCo4ZrqilB+DR2JFpd6W4k= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1774453619; x=1774460819; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=QlVvGqcwTWnjtiPgMXbtOTFaYx6UFRPdEulQrTJG0qU=; b=GeVHxiZ3jjOgJ794UqPa2/AKjU2Uzhu0VJAyth3At8L/YzuOmvUI5pMxc3zP1XVJgiOjQGS29tg/EeGHP8GNGjgBTLv1Qa6en6KtM6o3NFxsNfb/t9Z7NVJyITlDGHsiaPpunziu+MErmO+i3mUEIGSFDXAnexbYpirGxahPZGk= X-Mailgun-Sid: WyIxODZiYSIsInRqcGh1aHNAZ21haWwuY29tIiwiNGQxODU4Il0= X-Feedback-Id: postmaster@mg2.substack.com:post:5a78b6d5cd16820001f2a9d4:mailgun Received: by cac62463954cde4b542cbe0b2704dd5eea5cac1e3447d88b528ec7b22b84cfbc with HTTP id 69c40373cb3151bb4cd695df; Wed, 25 Mar 2026 15:46:59 GMT X-Mailgun-Sending-Ip: 159.112.244.47 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="e015def51034457ca83a8274d7abf53f40ceac7e1363b6a698e2b6776f18" Subject: Synergy Over Maximalism: The Part of Stacking Nobody Talks About From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260325154644.3.fe0dfafd8b768f8e@mg2.substack.com> Date: Wed, 25 Mar 2026 15:46:44 +0000 Feedback-Id: post-192108403:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1774453619338", "is_freemail": "true", "post_audience": "everyone", "post_id": "192108403", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --e015def51034457ca83a8274d7abf53f40ceac7e1363b6a698e2b6776f18 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/synergy-ove= r-maximalism-the-part A lot of you have seen the energy protocol. And a lot of you have messaged = me some version of the same question: =E2=80=9CIs that protocol not enough?= Why aren=E2=80=99t the research protocols higher?=E2=80=9D Let me break down exactly why =E2=80=94 because understanding this will cha= nge how you approach stacking research compounds in general First, What Are These Compounds Actually Doing in Research? Before we talk about research protocol strategy, you need to understand wha= t each of these compounds does at the cellular level in research contexts. = Don=E2=80=99t worry =E2=80=94 keeping it simple. Mitochondria are the power plants of cells. They take in nutrients and conv= ert them into ATP =E2=80=94 the actual energy currency cells run on. When m= itochondrial function declines, everything suffers: energy, cognition, reco= very, metabolism. That=E2=80=99s the target these compounds are being resea= rched against. Here=E2=80=99s how each compound in the protocol addresses that: SS-31 (Elamipretide) SS-31 works directly at the inner mitochondrial membra= ne in research models. It binds to a molecule called cardiolipin, which is = critical for keeping the electron transport chain =E2=80=94 the actual ATP-= production machinery =E2=80=94 running efficiently. Think of cardiolipin li= ke the structural scaffolding that holds the assembly line together. When i= t degrades, the whole process gets sloppy and produces a lot of oxidative w= aste (free radicals) instead of clean energy. SS-31 has been shown in resea= rch to stabilize that scaffolding and reduce oxidative leakage. MOTS-c MOTS-c is a peptide encoded directly within mitochondrial DNA =E2=80= =94 which makes it unusual. In research, it acts as a signaling molecule th= at activates AMPK, one of the master regulators of cellular energy balance.= When AMPK is activated, cells demonstrate improved utilization of glucose = and fatty acids as fuel, mitochondrial biogenesis (the creation of new mito= chondria) is promoted, and metabolic efficiency improves. Research suggests= MOTS-c essentially sends a signal from the mitochondria to the rest of the= cell: get more efficient. NAD+ NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at th= e center of energy metabolism in research models. It=E2=80=99s the electron= carrier that shuttles energy through the electron transport chain. It also= activates sirtuins =E2=80=94 proteins that regulate mitochondrial health, = DNA repair, and cellular stress responses. NAD+ levels decline significantl= y with age in research subjects, and when they drop, mitochondrial function= follows. Restoring NAD+ in research replenishes a core substrate the whole= system depends on. SLU-PP-332 SLU-PP-332 is an ERR (estrogen-related receptor) agonist being s= tudied in research settings. ERRs are transcription factors that regulate t= he genes responsible for mitochondrial biogenesis and oxidative metabolism.= Activating them in research models essentially signals cells to build more= mitochondria and upregulate the machinery that oxidizes fat for fuel. Earl= y research has shown significant improvements in exercise endurance and met= abolic output through this pathway. So Why Don=E2=80=99t You Just Max All of Them in Research? Here=E2=80=99s where the synergy piece comes in. Look at what these four compounds are collectively doing in research: SS-31 is protecting and optimizing existing mitochondria at the membrane le= vel MOTS-c is signaling cells to increase metabolic efficiency and build new mi= tochondria NAD+ is replenishing the core substrate the electron transport chain runs o= n SLU is activating the genes that drive mitochondrial biogenesis and fat oxi= dation These pathways are overlapping and reinforcing each other simultaneously in= research models. When all four are administered together in a research con= text, mitochondrial function is being addressed from multiple angles at onc= e. The combined effect observed in research is meaningfully greater than an= y single compound alone. That=E2=80=99s synergy. And synergy means you don=E2=80=99t need to push ea= ch individual compound to the protocol you=E2=80=99d use if it were the onl= y thing in the research stack. The Cagri + Tirz Analogy Let me make this concrete with an analogy most of you will immediately unde= rstand. Imagine researching Cagrilintide and Tirzepatide together in the same RS. B= oth suppress appetite through different mechanisms =E2=80=94 Cagrilintide t= hrough amylin receptor agonism, Tirzepatide through GIP and GLP-1 receptor = agonism. They overlap in observed outcome even if the pathways differ. Would you run each one at the full protocol you=E2=80=99d use if it were th= e only compound being researched in that RS? Of course not. If you did, you=E2=80=99d overshoot. The RS would experience= far more appetite suppression than the research calls for, you=E2=80=99d l= ose the ability to understand which compound is driving which response, and= you=E2=80=99d have no clean way to adjust. The right approach: introduce one compound, establish a baseline in the RS,= then layer in the second and gauge the additive effect before making any a= djustments. Mitochondrial peptides follow the same logic. If SS-31, MOTS-c, NAD+, and S= LU are all pushing mitochondrial output upward simultaneously in the RS, ru= nning each at its individual maximum protocol is redundant at best and coun= terproductive at worst. You lose signal, you lose control, and you=E2=80=99= re not using the synergy to your advantage =E2=80=94 you=E2=80=99re overloa= ding the system. The Right Mindset for Any Overlapping Research Stack This principle applies across the entire research space anywhere mechanisms= overlap: GH secretagogues stacked together (CJC, Ipamorelin, GHRP-2, etc.) Multiple GLP-1 pathway compounds in the same RS Cognitive peptides hitting overlapping neurological targets Healing peptides with shared anti-inflammatory mechanisms Whenever you=E2=80=99re stacking compounds that share a target or outcome i= n a research context, the protocol for each individual compound should come= down. The synergy is doing work that higher individual protocols would be = doing if run solo. Don=E2=80=99t pay twice for the same effect. The Full Energy Protocol If you haven=E2=80=99t seen it yet, I broke down the complete energy resear= ch protocol =E2=80=94 including compounds, protocols, and the reasoning beh= ind the stack =E2=80=94 over on Substack. All compounds are for research us= e only, not for human consumption. Read it here: https://derekpruski.substack.com/p/unlimited-energy-guide-bre= aking-down?r=3D4jq1x8 [ https://substack.com/redirect/008f5b1e-5dd0-4e51-84= 24-0bfd14186d2b?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtu= ZifRB-Zs ] Where any individual RS lands within that framework will vary. Some researc= h contexts will find the starting point sufficient. Others may build gradua= lly over time. There is no universal answer. Start low. Build deliberately. Let the stack do what it=E2=80=99s designed = to do. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNakV3T0RRd015d2lhV0YwSWpveE56YzBOR= FV6TmpFNUxDSmxlSEFpT2pFNE1EVTVPRGsyTVRrc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Llh3aDlpUTJtOXhMOF80dFRQR3FsUEdCZGZ= XaUl4Zy10Q2xaUU9JZnJwUkkiLCJwIjoxOTIxMDg0MDMsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc0NDUzNjE5LCJleHAiOjIwOTAwMjk2MTksImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.Z6OAicrbkLRkLP7MHr0t41akWbw_ct1qrIcHZjV= rQt0? --e015def51034457ca83a8274d7abf53f40ceac7e1363b6a698e2b6776f18 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Synergy Over Maximalism:= The Part of Stacking Nobody Talks About3D""
A lot of you have seen the energy protocol.
͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­
=
Forwarded t= his email? Subscribe here for m= ore
=

Synergy Over Maximalism: The Part of Stacking Nobody Talks Abo= ut

<= td align=3D"right">
Derek
 
=3D""
= 3D""
3D""
<= tr>
 

A lot of you have seen the energy protocol. A= nd a lot of you have messaged me some version of the same question: = “Is that protocol not enough? Why aren’t the research proto= cols higher?”

Let me break down exactly why R= 12; because understanding this will change how you approach stacking resear= ch compounds in general

<= td style=3D"text-align: center;">
3D""
Upgrade to = paid

First, What Are These Compoun= ds Actually Doing in Research?

Before we talk abou= t research protocol strategy, you need to understand what each of these com= pounds does at the cellular level in research contexts. Don’t worry &= #8212; keeping it simple.

Mitochondria are the power plants= of cells. They take in nutrients and convert them into ATP — the act= ual energy currency cells run on. When mitochondrial function declines, eve= rything suffers: energy, cognition, recovery, metabolism. That’s the = target these compounds are being researched against.

Here&#= 8217;s how each compound in the protocol addresses that:

SS-31 (Elamipretide) SS-31 works directly at the inner= mitochondrial membrane in research models. It binds to a molecule called c= ardiolipin, which is critical for keeping the electron transport chain R= 12; the actual ATP-production machinery — running efficiently. Think = of cardiolipin like the structural scaffolding that holds the assembly line= together. When it degrades, the whole process gets sloppy and produces a l= ot of oxidative waste (free radicals) instead of clean energy. SS-31 has be= en shown in research to stabilize that scaffolding and reduce oxidative lea= kage.

MOTS-c MOTS-c is a pept= ide encoded directly within mitochondrial DNA — which makes it unusua= l. In research, it acts as a signaling molecule that activates AMPK, one of= the master regulators of cellular energy balance. When AMPK is activated, = cells demonstrate improved utilization of glucose and fatty acids as fuel, = mitochondrial biogenesis (the creation of new mitochondria) is promoted, an= d metabolic efficiency improves. Research suggests MOTS-c essentially sends= a signal from the mitochondria to the rest of the cell: get mor= e efficient.

NAD+ NAD+ (nicotin= amide adenine dinucleotide) is a coenzyme that sits at the center of energy= metabolism in research models. It’s the electron carrier that shuttl= es energy through the electron transport chain. It also activates sirtuins = — proteins that regulate mitochondrial health, DNA repair, and cellul= ar stress responses. NAD+ levels decline significantly with age in research= subjects, and when they drop, mitochondrial function follows. Restoring NA= D+ in research replenishes a core substrate the whole system depends on.

SLU-PP-332 SLU-PP-332 is an ERR= (estrogen-related receptor) agonist being studied in research settings. ER= Rs are transcription factors that regulate the genes responsible for mitoch= ondrial biogenesis and oxidative metabolism. Activating them in research mo= dels essentially signals cells to build more mitochondria and upregulate th= e machinery that oxidizes fat for fuel. Early research has shown significan= t improvements in exercise endurance and metabolic output through this path= way.

So Why Don’t You Just Max All of T= hem in Research?

Here’s where the synergy pi= ece comes in.

Look at what these four compounds are collect= ively doing in research:

  • SS-31 is protecting and optimizi= ng existing mitochondria at the membrane level

  • MOTS-c is signaling cells to increase metabol= ic efficiency and build new mitochondria

  • NAD+ is replenishing the core substrate the electro= n transport chain runs on

  • SLU is activating the genes that drive mitochondrial biogenesis an= d fat oxidation

These pathways are overlapping an= d reinforcing each other simultaneously in research models. When all four a= re administered together in a research context, mitochondrial function is b= eing addressed from multiple angles at once. The combined effect observed i= n research is meaningfully greater than any single compound alone.

That’s synergy. And synergy means you don’t need to pus= h each individual compound to the protocol you’d use if it were the o= nly thing in the research stack.

The Cagri + Tirz Ana= logy

Let me make this concrete with an analogy mos= t of you will immediately understand.

Imagine researching C= agrilintide and Tirzepatide together in the same RS. Both suppress appetite= through different mechanisms — Cagrilintide through amylin receptor = agonism, Tirzepatide through GIP and GLP-1 receptor agonism. They overlap i= n observed outcome even if the pathways differ.

Would you r= un each one at the full protocol you’d use if it were the only compou= nd being researched in that RS?

Of course not. If you did, = you’d overshoot. The RS would experience far more appetite suppressio= n than the research calls for, you’d lose the ability to understand w= hich compound is driving which response, and you’d have no clean way = to adjust.

The right approach: introduce one compound, esta= blish a baseline in the RS, then layer in the second and gauge the additive= effect before making any adjustments.

Mitochondrial peptid= es follow the same logic. If SS-31, MOTS-c, NAD+, and SLU are all pushing m= itochondrial output upward simultaneously in the RS, running each at its in= dividual maximum protocol is redundant at best and counterproductive at wor= st. You lose signal, you lose control, and you’re not using the syner= gy to your advantage — you’re overloading the system.

The Right Mindset for Any Overlapping Research Stack<= /p>

This principle applies across the entire research space any= where mechanisms overlap:

  • GH secretagogues stacked togeth= er (CJC, Ipamorelin, GHRP-2, etc.)

  • Multiple GLP-1 pathway compounds in the same RS

    • <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

    Cognitive peptides hitting= overlapping neurological targets

  • Healing peptides with shared anti-inflammatory mechanisms<= /p>

Whenever you’re stacking compounds that sha= re a target or outcome in a research context, the protocol for each individ= ual compound should come down. The synergy is doing work that higher indivi= dual protocols would be doing if run solo. Don’t pay twice for the sa= me effect.

The Full Energy Protocol

If you haven’t seen it yet, I broke down the complete energ= y research protocol — including compounds, protocols, and the reasoni= ng behind the stack — over on Substack. All compounds are for researc= h use only, not for human consumption.

Read it here: = https://derekp= ruski.substack.com/p/unlimited-energy-guide-breaking-down?r=3D4jq1x8

Where any individual RS lands within that framework will vary= =2E Some research contexts will find th= e starting point sufficient. Others ma= y build gradually over time. There is no universal answer.

= Start low. Build deliberately. Let the stack do what it’s designed to= do.

Upgrade to paid

You're currently a f= ree subscriber to Peptide Pric= e. For the full experience, upgrade your subscription.

3D""Share

  
=
3D""Like=
3D""Comment
3D""Restack=
 

© 2026 Derek Prus= ki
548 Market Street PMB 72296, San Francisco, CA 94104
Unsubscribe

<= p class=3D"footerSection-EHR0jG small powered-by-substack" style=3D"padding= : 0 24px;font-size: 12px;line-height: 20px;margin: 0;color: rgb(119,119,119= );font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto= ,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI = Symbol';padding-bottom: 0;margin-top: 0;">3D"Start

3D""=3D"" --e015def51034457ca83a8274d7abf53f40ceac7e1363b6a698e2b6776f18--